Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly that targets three receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon
Semaglutide doses range from 0.25mg to 2.4mg, much lower than tirzepatide doses of 2.5mg to 15mg
Patients often report: Increased energy production and reduced fatigue Enhanced metabolism for weight management Improved DNA repair and cellular regeneration Protection against free radicals and oxidative stress Slower signs of aging with youthful vitality and mental clarity Convenient, Effective Treatment A 5ml vial dosed at 100mg twice a week will last 5weeks
Patients who are pregnant or planning to become pregnant should inform their healthcare provider
Check out our before and after photos above if you want to see what were talking about
As such, providers should position MIC B12 injections as adjunctive support, not as standalone solutions